Global E-commerce Company Announces Subsidiary Partnership With SpaceX Satellite Reseller

NKGen Biotech, Inc. (Nasdaq: NKGN), a clinical-stage biotechnology company, has announced that its innovative cryopreserved, autologous enhanced natural killer (NK) cell therapy, SNK01, has been cleared to progress into Phase 2 clinical development for the treatment of moderate Alzheimer’s disease. This advancement marks a milestone in the quest for effective treatments for one of the most challenging neurodegenerative diseases affecting millions globally. $NKGEN BIOTECH(NKGN.US)$